Zai Lab in-licensed rights to ZEJULA from Tesaro for China, Hong Kong and Macau as an important, new treatment option for more than 50,000 Chinese patients who suffer from ovarian cancer every year.

Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC PRESS RELEASE GlobeNewswire Oct. 5, 2020, 07:30 AM ...

SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the ...

Investors: Pete Rahmer / Mike ZanoniEndurance Advisors, on behalf of Zai Lab 415-515-9763 / 610-442-8570 [email protected] / [email protected] Zai Lab Limited Zai Lab Limited ...

For every dollar donated, another tree will be purchased and planted. Samantha Du, Ph.D., Founder, Chairperson and CEO of Zai Lab, has already committed an additional $10,000 to the effort.

Lung Cancer. 2021;161:108-113. About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United ...